SanFran,

I agree. You, and the rest of us shareholders, have a right to be frustrated with Zenith. The communication from Zenith has been disappointing. Seems like most of the information has been solicited from Zenith by members of this hub and spread on this board, and has not come directly from Zenith. Aside from you own posts San Fran, information has been provided from:

1) Masila's transcript of the Zenith special meeting on June 30th 2015

2) My inquiry to Sarah about RVX's scheduled presentation at the recent Boston epigenetics conference. Only after my inquiry did I find out that Eric Campeau from Zenith and not Norman Wong from RVX (as originally listed) would be presenting. Resverlogix/Zenith subsequently contacted the conference to reflect this change. Zenith now lists this event on their homepage but it wasn't there until just recently. This presentation (not webcast) was on ZEN-3694, which is supposodely their new lead oncology molecule that they hope to bring to clinical trials soon. How soon in the question.

3) Another inquiry to Sarah about the Zenith AGM. I asked "Will Zenith be hosting an annual general meeting this year, and if so when will it be?" to which she replied "Yes they are but the date has not been finalized. Once this information is ready for the public they will post it to the website."

Best,

BearDownAZ